An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS

Acute myeloid leukemia (AML) is characterized by clonal proliferation of neoplastic myeloid precursor cells resulting in impaired hematopoiesis. Despite initial responses to intensive induction therapy, relapses are frequent and most patients die in less than 5 years (National Cancer Institute 2015)...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2019-11, Vol.134 (Supplement_1), p.3926-3926
Hauptverfasser:	Kadia, Tapan M., Borthakur, Gautam M., Jabbour, Elias, Konopleva, Marina Y, Ravandi, Farhad, DiNardo, Courtney D., Zheleva, Daniella, Blake, David, Chiao, Judy H
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!